| Literature DB >> 28297568 |
Scott M Riester1, Janet M Denbeigh1, Yang Lin1,2, Dakota L Jones1,3, Tristan de Mooij1, Eric A Lewallen1, Hai Nie1, Christopher R Paradise1, Darcie J Radel4, Amel Dudakovic1, Emily T Camilleri1, Dirk R Larson5, Wenchun Qu6,7, Aaron J Krych1, Matthew A Frick8, Hee-Jeong Im9,10,11,12, Allan B Dietz4, Jay Smith6,8,13, Andre J van Wijnen1,3,14.
Abstract
Adipose-derived mesenchymal stem cells (AMSCs) offer potential as a therapeutic option for clinical applications in musculoskeletal regenerative medicine because of their immunomodulatory functions and capacity for trilineage differentiation. In preparation for a phase I clinical trial using AMSCs to treat patients with osteoarthritis, we carried out preclinical studies to assess the safety of human AMSCs within the intra-articular joint space. Culture-expanded human AMSCs grown in human platelet-lysate were delivered via intra-articular injections into normal healthy rabbit knees and knees at risk for the development of osteoarthritis after bilateral medial anterior hemimeniscectomy. Treatment outcomes and safety were evaluated by assessing the general health, function, and behavior of the animals. Joint tissues were analyzed by x-ray, magnetic resonance imaging, and histopathology. Intra-articular AMSC therapy was well tolerated in this study. We did not observe adverse systemic reactions, nor did we find evidence of damage to intra-articular joint tissues. Thus, the data generated in this study show a favorable safety profile for AMSCs within the joint space in support of a phase I clinical trial evaluating the clinical utility of AMSCs to treat osteoarthritis. Stem Cells Translational Medicine 2017;6:910-922.Entities:
Keywords: Cell therapy; Osteoarthritis; Rabbit; Regenerative medicine; Stem cell; Transplant
Mesh:
Year: 2016 PMID: 28297568 PMCID: PMC5442773 DOI: 10.5966/sctm.2016-0097
Source DB: PubMed Journal: Stem Cells Transl Med ISSN: 2157-6564 Impact factor: 6.940